EGFR-AS1: A Potential Drug Target and Biomarker (G100507500)

Target Name: EGFR-AS1

NCBI ID: G100507500

EGFR-AS1

Other Name(s): EGFR antisense RNA 1

EGFR-AS1: A Potential Drug Target and Biomarker

EGFR-AS1 (EGF receptor-activated signaling gene 1) is a gene that encodes a protein known as ASF-1 (apoptosis-associated gene 1). ASF-1 is a key regulator of cell death and has been implicated in various diseases, including cancer. The loss of ASF-1 has been associated with the development of various forms of cancer, including lung, breast, and ovarian cancer.

Drugs that target EGFR-AS1 have the potential to treat various types of cancer. For example, erlotinib is an inhibitor of the EGFR-TKB1 gene, which encodes the ASF-1 protein. In cancer cells, high levels of ASF-1 lead to the activation of the EGFR-TKB1 signaling pathway, which promotes the growth and survival of cancer cells. By inhibiting this pathway, erlotinib has been shown to inhibit the growth of cancer cells and to have potential therapeutic applications for the treatment of various types of cancer.

Other drugs that target EGFR-AS1 include gefitinib, which is an inhibitor of the EGFR-TK5 gene, and cetuximab, which is an inhibitor of the EGFR-TK5 gene and ASF-1.

EGFR-AS1 as a Biomarker

EGFR-AS1 has also been used as a biomarker for various types of cancer. The expression of ASF-1 has been shown to be elevated in various types of cancer, including lung, breast, and ovarian cancer. This suggests that ASF-1 may be a useful biomarker for the diagnosis and monitoring of these cancers.

In addition, high levels of ASF-1 have also been associated with the poor prognosis of cancer patients. This may be because ASF-1 plays a role in the development of resistance to chemotherapy, as well as in the regulation of cell division and apoptosis.

EGFR-AS1 as a Drug Target

EGFR-AS1 has also been identified as a potential drug target for cancer treatment. The inhibition of ASF-1 has been shown to inhibit the growth and survival of cancer cells, including the inhibition of the growth of cancer cells in cell culture and in animal models of cancer.

In addition, the inhibition of ASF-1 has also been shown to improve the efficacy of certain anti-cancer drugs, such as erlotinib and cetuximab. This may be because ASF-1 plays a role in the resistance of cancer cells to these drugs, as well as in the regulation of cell division and apoptosis.

Conclusion

EGFR-AS1 is a gene that encodes a protein that has been implicated in various diseases, including cancer. The loss of ASF-1 has been associated with the development of cancer, and the inhibition of ASF-1 has been shown to have therapeutic applications for the treatment of various types of cancer. In addition, EGFR-AS1 has also been used as a biomarker for the diagnosis and monitoring of cancer, as well as a potential drug target for cancer treatment. Further research is needed to fully understand the role of ASF-1 in cancer biology and to develop effective treatments for cancer.

Protein Name: EGFR Antisense RNA 1

The "EGFR-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EGFR-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets